Search

Background: Since December 2019, a novel coronavirus (2019-nCoV) associated pneumonia has emerged in Wuhan, China. The study aimed to further clarify the epidemiological and clinical characteristics of 2019-nCoV pneumonia. Methods: 99 cases admitted to Wuhan Jinyintan Hospital during January 1 to 20, 2020 and confirmed by real-time reverse-transcriptase polymerase-chain-reaction (RT-PCR) test were analyzed for epidemiological, demographic, clinical, radiological features, and laboratory data. Findings: Of the 99 patients with 2019-nCoV pneumonia, 49 (49%) had a history of exposure to the South China Seafood Wholesale Market. The average age of the patients was 62.85 ± 11.99 years, including 67 males and 32 females. 2019-nCoV was detected in all patients by RT-PCR, and some of them also by serological testing, and metagenomics sequencing analysis. 50 cases (50.51%) had chronic basic diseases. Patients had clinical manifestations of fever (83%), cough (82%), shortness of breath (31%), muscle aches (11%), headache (8%), fuzzy confusion (7%), chest pain (2%), and diarrhea (2%). According to imaging examination, 74 patients showed bilateral pneumonia (74.75%), 25 patients showed multiple mottled and ground-glass opacity, and 1 patient had pneumothorax. Most patients received antiviral, antibiotics, supportive treatments, continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO), and had good prognosis. 17 patients developed acute Respiratory Distress Syndrome (ARDS) and among them, 2 patients worsened in a short period of time and died of multiple organ failure. Interpretation: The infection of the 2019-nCoV can result in severe and even fatal respiratory disease like ARDS. It is very important to actively prevent complications and secondary infections, treat underlying diseases, and provide timely organ function support. Early diagnosis, early isolation, multiple treatment, and intervention of CRRT and ECMO when necessary can effectively reduce mortality caused by severe coronavirus pneumonia. Funding: National Key R&D Program of China (No. 2017YFC1309700) Declaration of Interest: The author reports no conflicts of interest in this work. Ethical Approval: The study was approved by Jinyintan Hospital Ethics Committee and written informed consent was obtained from all patients involved before enrolment.

Purpose: Preeclampsia (PE) is a common complication during pregnancy that seriously affects the health of both the mother and child due to its insidious onset and delayed diagnosis. Therefore, a retrospective evaluation is necessary for developing a clinical nomogram for predicting prognosis among PE patients. Methods: We developed a nomogram to predict PE prognosis based on 5058 patients recruited from Shandong Province, China between January 2012 and November 2017; then, we externally validated the nomogram in a separate cohort of 1947 patients across China by testing the calibration and discrimination of the nomogram in predicting the delivery time among PE patients. Results: According to forward stepwise linear regression analyses, the time of hypertension onset (TOH) is the most predictive factor in the prognosis of patients with PE, followed by the urine protein, serum creatinine, and alkaline phosphatase levels and ten other clinical parameters. Then, we developed a prognostic visualized nomogram and a risk assessment table to predict the outcome of PE patients and found that PE patients with high scores may have an earlier delivery time; this finding was validated by performing calibration and discrimination analyses, and the agreement between the nomogram predictions and actual delivery times was excellent in both the primary and validation cohorts. In addition, this nomogram could estimate the fetal prognosis. Conclusion: We established and validated a nomogram that can predict the prognosis of PE patients. This practical prognostic PE model may be helpful for clinicians in making clinical decisions and providing treatment. Funding Statement: This work was supported by the National Key Research and Development Program of China (2016YFC1000300), the National Natural Science Foundation of China (81371499, 81170688, 81470973, and 81770679), the Shandong Provincial Natural Science Foundation, China (ZR2009CM094). Declaration of Interests: The authors declare there is no potential conflict of interests. Ethics Approval Statement: Ethical approval was obtained from the Institutional Review Boards by the respective participating institutions, and all PE patients provided signed written informed consent.